Cargando…
Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma
Hepatic epithelioid hemangioendothelioma (HEH) is a very rare tumor originating from vascular endothelial cells, with unpredictable malignancy. At present, there is no standard treatment protocol yet established. Both surgical resection and liver transplantation have been reported to be effective tr...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755491/ https://www.ncbi.nlm.nih.gov/pubmed/36530920 http://dx.doi.org/10.3389/fmed.2022.1022017 |
_version_ | 1784851431907393536 |
---|---|
author | Liu, Xiaolei Zhou, Ruiquan Si, Shuang Liu, Liguo Yang, Shiwei Han, Dongdong Tan, Haidong |
author_facet | Liu, Xiaolei Zhou, Ruiquan Si, Shuang Liu, Liguo Yang, Shiwei Han, Dongdong Tan, Haidong |
author_sort | Liu, Xiaolei |
collection | PubMed |
description | Hepatic epithelioid hemangioendothelioma (HEH) is a very rare tumor originating from vascular endothelial cells, with unpredictable malignancy. At present, there is no standard treatment protocol yet established. Both surgical resection and liver transplantation have been reported to be effective treatments for HEH; however, multiple intrahepatic lesions or extrahepatic metastasis make these procedures unsuitable to most patients. Systematic therapy has also been investigated, but the results are undetermined due to the limited cases. Interferon-alpha 2b (IFN-a 2b) has also been used for the treatment of HEH. Based on our previous study, the rate of tumor regression with IFN-a 2b monotherapy was more than 50%. Here, we reported a patient with advanced HEH, who achieved a partial response with the combined therapy of anlotinib and IFN-a 2b. The tumor stayed stable for 2 years with anlotinib monotherapy and regressed 3 months after the combined therapy of anlotinib and IFN-a 2b. The synergistic effect of combined therapy with anlotinib and IFN-a 2b provided promising guidance for future clinical study. |
format | Online Article Text |
id | pubmed-9755491 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97554912022-12-17 Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma Liu, Xiaolei Zhou, Ruiquan Si, Shuang Liu, Liguo Yang, Shiwei Han, Dongdong Tan, Haidong Front Med (Lausanne) Medicine Hepatic epithelioid hemangioendothelioma (HEH) is a very rare tumor originating from vascular endothelial cells, with unpredictable malignancy. At present, there is no standard treatment protocol yet established. Both surgical resection and liver transplantation have been reported to be effective treatments for HEH; however, multiple intrahepatic lesions or extrahepatic metastasis make these procedures unsuitable to most patients. Systematic therapy has also been investigated, but the results are undetermined due to the limited cases. Interferon-alpha 2b (IFN-a 2b) has also been used for the treatment of HEH. Based on our previous study, the rate of tumor regression with IFN-a 2b monotherapy was more than 50%. Here, we reported a patient with advanced HEH, who achieved a partial response with the combined therapy of anlotinib and IFN-a 2b. The tumor stayed stable for 2 years with anlotinib monotherapy and regressed 3 months after the combined therapy of anlotinib and IFN-a 2b. The synergistic effect of combined therapy with anlotinib and IFN-a 2b provided promising guidance for future clinical study. Frontiers Media S.A. 2022-12-02 /pmc/articles/PMC9755491/ /pubmed/36530920 http://dx.doi.org/10.3389/fmed.2022.1022017 Text en Copyright © 2022 Liu, Zhou, Si, Liu, Yang, Han and Tan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Liu, Xiaolei Zhou, Ruiquan Si, Shuang Liu, Liguo Yang, Shiwei Han, Dongdong Tan, Haidong Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma |
title | Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma |
title_full | Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma |
title_fullStr | Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma |
title_full_unstemmed | Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma |
title_short | Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma |
title_sort | case report: successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755491/ https://www.ncbi.nlm.nih.gov/pubmed/36530920 http://dx.doi.org/10.3389/fmed.2022.1022017 |
work_keys_str_mv | AT liuxiaolei casereportsuccessfultreatmentwiththecombinedtherapyofinterferonalpha2bandanlotinibinapatientwithadvancedhepaticepithelioidhemangioendothelioma AT zhouruiquan casereportsuccessfultreatmentwiththecombinedtherapyofinterferonalpha2bandanlotinibinapatientwithadvancedhepaticepithelioidhemangioendothelioma AT sishuang casereportsuccessfultreatmentwiththecombinedtherapyofinterferonalpha2bandanlotinibinapatientwithadvancedhepaticepithelioidhemangioendothelioma AT liuliguo casereportsuccessfultreatmentwiththecombinedtherapyofinterferonalpha2bandanlotinibinapatientwithadvancedhepaticepithelioidhemangioendothelioma AT yangshiwei casereportsuccessfultreatmentwiththecombinedtherapyofinterferonalpha2bandanlotinibinapatientwithadvancedhepaticepithelioidhemangioendothelioma AT handongdong casereportsuccessfultreatmentwiththecombinedtherapyofinterferonalpha2bandanlotinibinapatientwithadvancedhepaticepithelioidhemangioendothelioma AT tanhaidong casereportsuccessfultreatmentwiththecombinedtherapyofinterferonalpha2bandanlotinibinapatientwithadvancedhepaticepithelioidhemangioendothelioma |